Ignite Creation Date:
2025-12-25 @ 4:30 AM
Ignite Modification Date:
2026-01-29 @ 12:52 PM
Study NCT ID:
NCT05722418
Status:
RECRUITING
Last Update Posted:
2025-09-25
First Post:
2022-12-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor:
Caribou Biosciences, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CB11A
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None